980-Nm Diode Laser Vaporization versus Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia: Randomized Controlled Study

被引:7
|
作者
Cetinkaya, Mehmet [1 ]
Onem, Kadir [2 ]
Rifaioglu, Mehmet Murat [3 ]
Yalcin, Veli [4 ]
机构
[1] Mugla Sitki Kocman Univ, Sch Med, Dept Urol, Mugla, Turkey
[2] Ondokuz Mayis Univ, Ondokuz Mayis Med Fac, Dept Urol, Samsun, Turkey
[3] Mustafa Kemal Univ, Fac Med, Dept Urol, Antakya, Turkey
[4] Istanbul Univ, Cerrahpasa Med Fac, Dept Urol, Istanbul, Turkey
关键词
ablation techniques; lasers; semiconductor; therapeutic use; prostatic neoplasms; surgery; transurethral resection of prostate; urinary bladder neck obstruction; urinary catheterization; PHOTOSELECTIVE VAPORIZATION; KTP LASER; ABLATION; TRIAL; HYPERTROPHY; PREVALENCE;
D O I
暂无
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
Purpose: We compared the effectiveness and complications of 980-nm diode laser vaporization and transurethral resection of the prostate (TURP) in patients with benign prostatic hyperplasia (BPH). Materials and Methods: In total, 72 consecutive patients with BPH entered the study. All patients underwent general and urological evaluations. The primary outcome was improvement in the International Prostate Symptom Score (IPSS). The secondary outcomes were IPSS quality of life (QoL), maximum urinary flow rate (Qmax), residual volume, and complications. Patients were allocated randomly to the TURP and laser groups. The Ceralas HPD120, a diode laser system emitting at a wavelength of 980 nm, was used for photoselective vaporization of the prostate (PVP). TURP was performed with a monopolar 26 French resectoscope. Preoperative and operative parameters and surgical outcomes were compared. Results: In total, 36 patients in each group underwent PVP and TURP. The mean age standard deviation was 63.1 +/- 9.1 years and 64.7 +/- 10.2 years in the PVP and TURP groups, respectively. There were no statistically significant differences in age, prostate size, prostate-specific antigen concentration, Qmax, preoperative IPSS, or preoperative Qmax between the two groups. The operation duration was also similar between the groups (P =.36). The catheterization time was 1.45 +/- 0.75 and 2.63 +/- 0.49 days in the PVP and TURP groups, respectively (P <.01). The PVP group had a shorter hospital stay than the TURP group. The 3-month postoperative Qmax increased to 9.90 +/- 3.61 and 6.59 +/- 6.06 mL/s from baseline in the TURP and PVP groups, respectively; there was no difference in the increases between the groups (P =.08). The IPSS and IPSS-QoL were significantly improved with the operation (P <.01), and this improvement was similar in both groups P=.3 and P=.8, respectively. The complication rate was also similar between the two groups. Conclusions: PVP with a diode laser is as safe and effective as TURP in the treatment of BPH, and the techniques have similar complication rates and functional results. PVP has the advantage of shorter hospitalization and catheter indwelling times and no need for discontinuation of anticoagulant therapy.
引用
收藏
页码:2355 / 2361
页数:7
相关论文
共 50 条
  • [1] Diode Laser (980 nm) Vaporization in Comparison With Transurethral Resection of the Prostate for Benign Prostatic Hyperplasia: Randomized Clinical Trial With 2-year Follow-up
    Razzaghi, Mohammad Reza
    Mazloomfard, Mohammad Mohsen
    Mokhtarpour, Hooman
    Moeini, Aida
    [J]. UROLOGY, 2014, 84 (03) : 526 - 532
  • [2] Outcome of 980 nm diode laser vaporization for benign prostatic hyperplasia: A prospective study
    Mithani, M. Hammad
    El Khalid, Salman
    Khan, Shariq Anis
    Sharif, Imran
    Awan, Adnan Siddiq
    Mithani, Shoaib
    Majeed, Irfan
    [J]. INVESTIGATIVE AND CLINICAL UROLOGY, 2018, 59 (06) : 392 - 398
  • [3] Evaluation of photoselective vaporization of the prostate with 980-nm diode laser in the treatment of benign prostatic hyperplasia: 36-month follow up
    Huang, Lin
    Fan, Yongyi
    Xiong, Ni
    Tang, Zhen
    Wu, Minggui
    [J]. INTERNATIONAL JOURNAL OF UROLOGY, 2019, 26 (09) : 940 - 941
  • [4] Initial Experiences with a 980 nm Diode Laser for Photoselective Vaporization of the Prostate for the Treatment of Benign Prostatic Hyperplasia
    Yang, Ki Su
    Seong, Youl Keun
    Kim, In Gon
    Han, Bo Hyun
    Kong, Geun Soo
    [J]. KOREAN JOURNAL OF UROLOGY, 2011, 52 (11) : 752 - 756
  • [5] Transurethral 1470?nm diode laser vaporization versus plasma kinetic enucleation of the prostate for the treatment of benign prostatic hyperplasia: A retrospective study
    Huang, Jiaguo
    Fan, Yi
    Wang, Kai
    Ding, Hongxiang
    Mao, Dikai
    Zhao, Liwei
    Tai, Shengcheng
    [J]. MEDICINE, 2023, 102 (34) : E35031
  • [6] Randomized study of transurethral resection of the prostate and combined transurethral resection and vaporization of the prostate as a therapeutic alternative in men with benign prostatic hyperplasia
    Küpeli, S
    Yilmaz, E
    Soygür, T
    Budak, M
    [J]. JOURNAL OF ENDOUROLOGY, 2001, 15 (03) : 317 - 321
  • [7] 980-nm diode laser:: A novel laser technology for vaporization of the prostate
    Wendt-Nordahl, Gunnar
    Huckele, Stephanie
    Honeck, Patrick
    Alken, Peter
    Knoll, Thomas
    Michel, Maurice Stephan
    Haecker, Axel
    [J]. EUROPEAN UROLOGY, 2007, 52 (06) : 1723 - 1728
  • [8] Evaluation of learning curves for contact laser vaporization of the prostate using the 980 nm diode laser for benign prostatic hyperplasia
    Furumido, Jun
    Ozaki, Nariaki
    Matsugase, Yasukuni
    Mori, Tatsuya
    [J]. INTERNATIONAL JOURNAL OF UROLOGY, 2024, 31 (08) : 921 - 926
  • [9] A randomized prospective study of laser ablation of the prostate versus transurethral resection of the prostate in men with benign prostatic hyperplasia
    Shingleton, WB
    Terrell, F
    Renfroe, DL
    Kolski, JM
    Fowler, JE
    [J]. UROLOGY, 1999, 54 (06) : 1017 - 1021
  • [10] Photoselective vaporization with green laser versus monopolar transurethral resection for benign prostatic hyperplasia
    Silvinato, Antonio
    Floriano, Idevaldo
    Bernardo, Wanderley Marques
    [J]. REVISTA DA ASSOCIACAO MEDICA BRASILEIRA, 2024, 70 (08):